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Comparison of Early Clinical Results of Transcatheter versus 
Surgical Aortic Valve Replacement in Symptomatic 
High Risk Severe Aortic Stenosis Patients
Woo Sik Yu, M.D.1, Byung-Chul Chang, M.D., Ph.D.1, Hyun Chel Joo, M.D.1, 
Young-Guk Ko, M.D., Ph.D.2, Sak Lee, M.D., Ph.D.1
Background: Transcatheter aortic valve implantation (TAVI) has been an alternative to conventional aortic valve re-
placement (AVR) in old and high risk patients. The goal of this study is to compare the early outcomes of con-
ventional AVR vs. TAVI in high risk severe AS patients. Methods: From January 2008 to July 2012, 44 high risk 
severe aortic stenosis patients underwent conventional AVR, and 15 patients underwent TAVI. We compared echo-
cardiographic data, periprocedural complication, and survival. The mean follow-up duration was 14.5±10 months 
(AVR), and 6.8±3.5 months (TAVI), respectively. Results: AVR group was younger (78.2±2.4 years vs. 82.2±3.0 
years, p＜0.001) and had lower operative risk (Euroscore: 9.4±2.7 vs. 11.0±2.0, p=0.044) than TAVI group. There 
was no significant difference in early mortality (11.4% vs. 13.3%, p=0.839), and 1 year survival (87.4%±5.3% vs. 
83.1%±1.1%, p=0.805). There was no significant difference in postoperative functional class. There was no sig-
nificant difference in periprocedural complication except vascular complication (0% [AVR] vs. 13.3% [TAVI], p=0.014). 
TAVI group had more moderate and severe paravalvular leakage. Conclusion: In this study, both groups had sim-
ilar periprocedural morbidity, and mortality. However, TAVI group had more greater than moderate paravalvular leak-
age, which can influence long-term outcome. Since more patients are treated with TAVI even in moderate risk, 
careful selection of the patients and appropriate guideline need to be established.
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INTRODUCTION
Symptomatic severe aortic stenosis (AS) is a progressive 
disease with a poor prognosis if surgical intervention is not 
performed [1]. Conventional surgical aortic valve replacement 
(AVR) through median sternotomy under cardiopulmonary 
bypass is the treatment of choice [2]. However, the number 
of high-risk elderly patients has been increasing, with the ag-
ing of the population and increase in those who do not want 
to have their chest opened [3]. Recently, transcatheter aortic 
valve implantation (TAVI) was introduced and became an at-
tractive alternative therapy in these patients. In TAVI, a bio-
prosthetic valve is introduced percutaneously through a cathe-
ter, usually via the femoral artery, or less often, via the left 
ventricular apex (transapical approach) through thoracotomy. 
Furthermore, significant improvement of survival and quality 
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Table 1. Surgical procedures
Variable
AVR 
(n=44)
TAVI 
(n=15)
p-value
Isolated AVR
  With concomitant procedure
    With CABG
    With aorta surgery
    With MV surgery
    With TV surgery
    With CABG and aorta surgery
    With CABG and MV surgery
    With MV surgery and aorta 
 surgery
    With MV and TV surgery
Trans-femoral
Trans-aortic
Trans-subclavian
Operation time (min)
Cardiopulmonary bypass time (min)
Aortic cross-clamp time (min)
19
25
 9
 6
 4
 1
 1
 1
 2
 1
253±71
126±34
 98±29
12
 2
 1
108±67 ＜0.001
AVR, aortic valve replacement; TAVI, transcatheter aortic valve 
implantation; CABG, coronary artery bypass grafting; MV, mi-
tral valve; TV, tricuspid valve.
of life after TAVI has been reported [4], and now there is a 
trend toward performing TAVI in healthier patients [5].
Although surgical AVR with excellent outcomes has been 
reported in aged and high-risk patients [6], the high risk of 
developing a complete AV block requiring permanent pace-
maker implantation, paravalvular leakage that can negatively 
affect survival, and high costs are still problems associated 
with TAVI [7]. Therefore, we aimed to compare the early 
outcomes of conventional AVR and TAVI in high-risk severe 
AS patients.
METHODS
Between January 2008 and July 2012, 412 cases of surgi-
cal AVR with or without a concomitant procedure were per-
formed at Yonsei Cardiovascular Center, Yonsei University 
College of Medicine. Among these patients, 44 patients aged 
≥75 years with one or more comorbidities were included 
(AVR group). Fifteen patients who underwent TAVI during 
the same time period were also included for comparison 
(TAVI group).
The patients’ clinical characteristics, echocardiographic in-
dicators, and surgical data were obtained from a review of 
the medical records, and follow-up was performed by review-
ing hospital charts or conducting telephone interviews. Trans-
thoracic echocardiography and coronary angiography were 
routinely performed preoperatively in the AVR group, and 
transthoracic echocardiography, transesophageal echocardiog-
raphy, coronary angiography, and computed tomographic (CT) 
angiography were routinely performed to assess valvular mor-
phology and vascular access in the TAVI group. TAVI was 
first used in 2010, and since then, the decision between 
TAVI and surgical AVR was made in each patient by the 
medical and surgical team according to the severity of the 
clinical symptoms, combined comorbid diseases, physical per-
formance status, echocardiographic parameters, and vascular 
access.
Surgical AVR was performed through median sternotomy, 
under cardiopulmonary bypass and mild hypothermia, and 
concomitant valvular, coronary, or aortic surgery was per-
formed in 25 patients (Table 1). TAVI procedures were per-
formed with AccuTrak (The CoreValve system; Medtronic, 
Minneapolis, MN, USA) under general anesthesia in all of 
the patients. The prosthetic valve was inserted in retrograde 
fashion through a femoral artery (n=12), a subclavian artery 
(n=1), or an ascending aorta (n=2) (Table 1). Immediately af-
ter deployment of the prosthetic valve, transesophageal echo-
cardiography was performed to confirm the location and mo-
tion of the prosthetic valve, and any significant paravalvular 
leakage.
We compared in-hospital and early clinical outcomes of 
surgical AVR and TAVI using medical and echocardiographic 
data. All-cause mortality and incidence of complications in-
cluding pneumonia, neurologic deficit due to cerebrovascular 
accident, gastrointestinal bleeding requiring endoscopic inter-
vention, mediastinal bleeding requiring re-operation, renal 
failure requiring dialysis, new onset atrial fibrillation, vascular 
complication, complete atrioventricular block requiring perma-
nent pacemaker implantation, readmission due to heart failure 
aggravation or another cause, and pericardial effusion were 
analyzed.
All data are expressed as mean±standard deviation and fre-
quency and percentage. Continuous variables were compared 
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Table 2. Patients’ characteristics
Characteristic AVR (n=44) TAVI (n=15) p-value
Age (yr)
Female (%)
Body mass index (kg/m2)
Diabetes mellitus
COPD or FEV1＜80
Renal failure (eGFR＜60 mL/min)
Pulmonary hypertension (RVP＞55 mmHg)
Atrial fibrillation
Pacemaker
Cerebrovascular accident
Peripheral arterial occlusive disease
Coronary artery occlusive disease
Previous open heart surgery
Mitral regurgitation
Left ventricular ejection fraction (%)
Euroscore
NYHA Fc
  II
  III or IV
Follow-upduration (mo)
 78.2±2.417
  23 (52.3)
23.85±3.35
  11 (25)
  15 (34)
  21 (47.7)
   7 (15.9)
  12 (27.3)
   3 (6.8)
   6 (13.6)
   4 (9.1)
  20 (45)
   2 (4.5)
   9 (20.5)
 58.3±14.3
  9.4±2.7
  10 (22.7)
  34 (77.3)
 14.5±10
 82.2±3.075
   9 (60)
20.98±3.35
   1 (6.7)
   5 (33.3)
   8 (53.3)
   1 (6.7)
   3 (20)
   0 (0)
   1 (6.7)
   6 (40)
  11 (73)
   2 (13.3)
   0 (0)
 63.4±11.0
 11.0±2.0
   2 (13.3)
  13 (86.7)
  6.8±3.5
＜0.001
0.604
0.006
0.128
0.957
0.708
0.367
0.576
0.299
0.471
0.006
0.062
0.265
0.057
0.213
0.044
0.435
0.435
＜0.001
Values are presented as mean±standard deviation or number (%).
AVR, aortic valve replacement; TAVI, transcatheter aortic valve implantation; COPD, chronic obstructive pulmonary disease; FEV1, 
forced expiratory volume in 1 second; eGFR, estimated glomerular filtration rate; RVP, right ventricular pressure; NYHA Fc, New 
York Heart Association functional classification.
using the t-test, and categorical variables were compared us-
ing the chi-square test or Fisher’s exact test. Survival was 
evaluated with the Kaplan-Meier method, and the log-rank 
test was used to compare the groups. All statistical analyses 
were performed using SPSS ver. 17.0 (SPSS Inc., Chicago, 
IL, USA).
RESULTS
1) Patient characteristics
The patient characteristics of the AVR group and TAVI 
group are summarized in Table 2. The AVR group was 
younger (mean age: 78.2±2.4 years [range, 76 to 87 years] 
vs. 82.2±3.0 years [range, 75 to 85 years], p＜0.001), and 
had lower operative risks (Euroscore: 9.4±2.7 vs. 11.0±2.0, 
p=0.044). The TAVI group had a lower body mass index 
(23.85±3.35 kg/m2 vs. 20.98±3.35 kg/m2, p=0.006) and had 
more peripheral vascular disease (4 [9.1%] vs. 6 [40%], 
p=0.006).
2) Operative data
Nineteen patients in the AVR group underwent isolated 
AVR, and 25 patients underwent AVR with a concomitant 
valvular, coronary, or aortic procedure. Coronary artery by-
pass grafting (CABG) was most frequently performed con-
comitantly with AVR. The operation time was significantly 
longer in the AVR group (Table 1).
3) Clinical outcomes
The clinical outcomes are summarized in Table 3. The 
AVR group had significantly longer intensive care unit (ICU: 
6.09±7.97 days vs. 3.20±1.74 days, p=0.030) and hospital 
stays than the TAVI group (15.36±13.59 days vs. 7.13±3.18 
days, p≤0.001). There was no significant difference in hospi-
tal mortality or one-year survival between the two groups 
(87.4%±5.3% [AVR group] vs. 83.1%±1.1% [TAVI group], 
p=0.805) (Fig. 1). The causes of death were postoperative 
bleeding (n=1), gastrointestinal bleeding (n=1), sepsis (n=2), 
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Table 3. Clinical outcome
Variable AVR (n=44) TAVI (n=15) p-value
Intensive care unit stay (day)
Hospital stay (day)
Complications
  Pneumonia
  Stroke
  Gastrointestinal bleeding
  Renal failure requiring dialysis
  New onset atrial fibrillation
  Mediastinal bleeding
  Vascular complication
  Pacemaker insertion
  Readmission for heart failure aggravation
  Readmission for other causes
  Pericardial effusion
Postoperative NYHA Fc
  I
  II
  III, IV
Mortality
  30-day
  During follow-up
 6.09±7.97
15.36±13.59
   4 (9.1)
   3 (6.8)
   6 (13.6)
   3 (6.8)
   6 (13.6)
   2 (4.5)
   0 (0)
   2 (4.5)
   4 (9.1)
   3 (6.8)
   0 (0)
  30 (68.2)
   8 (18.2)
   0 (0)
   5 (11.4)
   2 (4.5)
   3 (6.8)
3.20±1.74
7.13±3.18
  2 (13.3)
  0 (0)
  2 (13.3)
  1 (6.7)
  0 (0)
  1 (6.7)
  2 (13.3)
  1 (6.7)
  1 (6.7)
  1 (6.7)
  1 (6.7)
  6 (40.0)
  6 (40.0)
  1 (6.7)
  2 (13.3)
  0 (0)
  2 (13.3)
0.030
＜0.001
0.639
0.299
0.976
0.984
0.131
0.747
0.014
0.747
0.771
0.984
0.084
0.053
0.086
0.084
0.839
0.401
0.434
Values are presented as mean±standard deviation or number (%).
AVR, aortic valve replacement; TAVI, transcatheter aortic valve implantation; NYHA Fc, New York Heart Association functional 
classification.
Fig. 1. Comparison of Kaplan-Meier estimated survival. AVR, aort-
ic valve replacement; TAVI, transcatheter aortic valve implantation.
Fig. 2. Comparison of (A) preoperative and (B) postoperative New 
York Heart Association (NYHA) functional classification.and pneumonia (n=1) in the AVR group, and pneumonia 
(n=1) and sepsis (n=1) in the TAVI group. The AVR group 
had greater improvement in the New York Heart Association 
functional class (NYHA Fc). However, this difference did not 
reach statistical significance (NYHA Fc I: 76.9% vs. 56.3%, 
p=0.037) (Fig. 2). There was no significant difference in peri-
procedural complications between the two groups except vas-
cular complications (0% [AVR group] vs. 13.3% [TAVI 
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Table 4. Echocardiographic data
Variable Preoperative
1st follow-up 
echocardiography
Last follow-up 
echocardiography
Time after operation
  AVR (n=39)
  TAVI (n=13)
Left ventricular ejection fraction (%)
  AVR (n=39)
  TAVI (n=13)
  p-valve
Paravalvular leak (≥moderate)
  AVR (n=39)
  TAVI (n=13)
  p-valve
60.1±12.7
61.5±10.5
0.721
 6.8±2.9 days
 0.1±0.3 days
64.0±7.8
57.7±13.0
  0.113
  0 (0)
  3 (23.1)
  0.002
 9.6±7.9 months
 4.4±2.7 months
63.2±11.7
63.8±10.2
  0.875
  0 (0)
  4 (30.8)
＜0.001
Values are presented as mean±standard deviation or number (%). Mortality cases were excluded.
AVR, aortic valve replacement; TAVI, transcatheter aortic valve implantation.
group], p=0.014). The causes of readmission other than heart 
failure aggravation were general weakness (n=2) and ag-
gravation of renal failure (n=1) in the AVR group, and pres-
sure sore management (n=2) in the TAVI group.
Echocardiographic outcomes from the survivors are sum-
marized in Table 4. The TAVI group had more moderate and 
severe paravalvular leakage at the first and last follow-up 
echocardiography. A complete AV block requiring pacemaker 
implantation developed in 3 patients (2 patients in the AVR 
group, and 1 patient in the TAVI group) without a significant 
difference between the two groups.
DISCUSSION
The prognosis in patients with symptomatic severe AS is 
poor if treated medically [1,8,9]. After symptom onset, the 
1-year mortality rate in patients with severe AS and without 
surgical AVR is around 30%, and surgical AVR is the treat-
ment of choice for patients with symptomatic severe AS 
[1,9]. However, the risk of surgical mortality increases sig-
nificantly with age and other comorbid conditions [10-12]. 
Therefore, the TAVI procedure is becoming an alternative 
therapeutic option in elderly patients with high risks, and 
with proven safety and efficacy, more patients aged over 80 
years who would have been candidates for surgical AVR are 
now undergoing TAVI [3,13-15].
The Placement of Aortic Transcatheter Valves (PARTNER) 
trial is a randomized trial to evaluate TAVI in humans. In 
PARTNER trial B, 358 patients who were considered in-
operable were randomly assigned to TAVI or standard 
therapy. TAVI significantly reduced mortality from all causes 
and cardiac symptoms. However, major stroke and vascular 
complications were more common in TAVI [4].
In PARTNER trial A, the results of isolated AVR and 
TAVI were compared in high-risk patients. Six hundred and 
ninety-nine patients were randomly assigned to AVR or 
TAVI. There was no significant difference in mortality 
(1-year mortality rate: 26.8% vs. 24.2%). Major bleeding and 
new-onset atrial fibrillation were more common in the AVR 
group. In addition, vascular complications and major stoke 
were more common in the TAVI group. There was no sig-
nificant difference in NYHA Fc at 1 year. More than moder-
ate AR due to paravalvular leakage was more common in the 
TAVI group [16].
In this study, the TAVI group had a similar 1-year survival 
to the AVR group despite the fact that TAVI was performed 
in older and higher risk patients. In addition, the TAVI group 
had a shorter operative time, and ICU and hospital stay 
durations. However, the AVR group had greater improvement 
in NYHA functional class. This may be related to 1) more 
favorable echocardiographic results (less paravalvular leakage) 
and 2) correction of other valvular pathology and coronary 
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artery occlusive disease by concomitant CABG and other 
valvular surgery.
Previous publications have reported that the 30-day mortal-
ity rate after TAVI ranges from 3.2% to 15.2% [4,13-16]. In 
this study, the early mortality in the TAVI group was 0.0%, 
and the rate of complete heart block was also lower than in 
previous reports. These low rates of mortality and complica-
tions may have been achieved due to meticulous preoperative 
evaluation and careful patient selection by a team approach 
(cardiologist, at least two surgeons, anesthesiologist, coor-
dinator, and surgical nursing staff). Therefore, the TAVI pro-
cedure should be performed by skillful surgeons following 
meticulous patient selection and pre-procedural planning, 
along with post-procedural care in strict compliance with rec-
ommendations from TAVI experts and accumulated data.
Chiappini et al. [17] reported excellent early and late out-
comes of AVR in octogenarians in 2004 (1-year survival: 
86.5% and 5-year survival: 69.4%). Subramanian et al. [18] 
also reported excellent outcomes of AVR in TAVI candidates 
(1-year survival: 87.5% and 3-year survival: 72.7%). In this 
study, the mean age of the patients was 80 years, and the 
early and mid-term follow-up results were satisfactory. The 
causes for TAVI denial in these patients were 1) large annu-
lus, 2) acceptable risk profile for AVR, 3) the need for an 
urgent operation, and 4) concomitant pathology that required 
a concomitant procedure.
The main limitation of this study was the small sample 
size and short follow-up duration. Because only one and a 
half years have passed since TAVI was first performed, a 
longer duration of follow-up with a larger population of 
randomized patients is required for more accurate comparison 
of the two treatment modalities.
In conclusion, TAVI is a good alternative treatment modal-
ity in inoperable or high-risk patients. However, the TAVI 
group had more frequent paravalvular leakage at a moderate 
level or higher, which can influence long-term outcomes. 
AVR can be performed in old and high risk patients with 
good results and an acceptable level of risk. Since more and 
more patients are treated with TAVI even at moderate risk, 
careful selection of the patients and an appropriate guideline 
need to be established.
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